NEW YORK, Dec. 07, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on HTGM, OPGN, ROKA, and DXCM which is a click away at http://www.wallstequities.com/registration. First Research reported that as access to health care expands around the world, the need for
HTG Molecular Diagnostics
On Wednesday, shares in Tucson, Arizona-based HTG Molecular Diagnostics Inc. recorded a trading volume of 150,814 shares. The stock ended the day at $1.88, declining 2.54% from the last trading session. The Company's shares have advanced 3.35% in the previous three months. The stock is trading below its 50-day moving average by 13.35%. Furthermore, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have a Relative Strength Index (RSI) of 38.93. Signing up now gives you access to the free research coverage on HTGM at: http://www.wallstequities.com/registration/?symbol=HTGM
Gaithersburg, Maryland headquartered OpGen Inc.'s stock saw a drop of 4.29%, finishing yesterday's session at $0.23 with a total trading volume of 1.50 million shares. The stock is trading below their 50-day moving average by 22.04%. Shares of the Company, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, an RSI of 37.04. Get access to our top-rated research, including the free report on OPGN at: http://www.wallstequities.com/registration/?symbol=OPGN
Shares in Warren, New Jersey headquartered Sorrento Tech Inc. ended the session 1.81% lower at $0.93. The stock recorded a trading volume of 109,804 shares. The Company's shares are trading 20.06% below their 50-day moving average. Moreover, shares of Sorrento Tech, which focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the US, have an RSI of 46.45. Click here to subscribe for a free membership which welcomes you with our report on ROKA at: http://www.wallstequities.com/registration/?symbol=ROKA
At the closing bell on Wednesday, San Diego, California headquartered DexCom Inc.'s stock rose 1.43%, finishing at $58.83. A total volume of 1.08 million shares was traded. The Company's shares have gained 17.80% in the last month. The stock is trading 16.66% above its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 77.81.
On November 27th, 2017, DexCom announced that Quentin Blackford, Executive Vice President, CFO; and Matthew Dolan, Vice President Corporate Development, will present an update on the Company at the BMO Prescriptions for Success Healthcare Conference on December 14th, 2017, at 11:00 a.m. EST in New York City. The presentation, which will occur live at The Westin Grand Central Hotel, will be concurrently webcast on the Company's website. To get free access to your research report on DXCM, sign up at: http://www.wallstequities.com/registration/?symbol=DXCM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-medical-researchs-investors----htg-molecular-diagnostics-opgen-sorrento-tech-and-dexcom-300568252.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All